Related Experiment Video
Updated: Dec 18, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
The RAS-interacting chaperone UNC119 drives the RASSF6-MDM2-p53 axis and antagonizes RAS-mediated malignant
Takanobu Shimizu1, Takeshi Nakamura1, Hironori Inaba2
1Department of Medical Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Abstract:
The gene encoding the proto-oncogene GTPase RAS is frequently mutated in human cancers. Mutated RAS proteins trigger antiapoptotic and cell-proliferative signals and lead to oncogenesis. However, RAS also induces apoptosis and senescence, which may contribute to the eradication of cells with RAS mutations. We previously reported that Ras association domain family member 6 (RASSF6) binds MDM2 and stabilizes the tumor suppressor p53 and that the active form of KRAS promotes the interaction between RASSF6 and MDM2. We also reported that Unc-119 lipid-binding chaperone (UNC119A), a chaperone of myristoylated proteins, interacts with RASSF6 and regulates RASSF6-mediated apoptosis. In this study, using several human cancer cell lines, quantitative RT-PCR, RNAi-based gene silencing, and immunoprecipitation/-fluorescence and cell biology assays, we report that UNC119A interacts with the active form of KRAS and that the C-terminal modification of KRAS is required for this interaction. We also noted that the hydrophobic pocket of UNC119A, which binds the myristoylated peptides, is not involved in the interaction. We observed that UNC119A promotes the binding of KRAS to RASSF6, enhances the interaction between RASSF6 and MDM2, and induces apoptosis. Conversely, UNC119A silencing promoted soft-agar colony formation, migration, and invasiveness in KRAS-mutated cancer cells. We conclude that UNC119A promotes KRAS-mediated p53-dependent apoptosis via RASSF6 and may play a tumor-suppressive role in cells with KRAS mutations.
Insights
Unc-119 lipid-binding chaperone A (UNC119A) promotes KRAS-driven apoptosis in cancer cells by stabilizing the p53 tumor suppressor. UNC119A silencing increases cancer cell growth and invasiveness, suggesting a tumor-suppressive role.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Proto-oncogene GTPase RAS mutations drive human cancers by promoting cell proliferation and inhibiting apoptosis.
- Ras association domain family member 6 (RASSF6) stabilizes p53 and interacts with MDM2, a key regulator of p53.
- Unc-119 lipid-binding chaperone A (UNC119A) is a chaperone for myristoylated proteins and interacts with RASSF6, regulating apoptosis.
Purpose of the Study:
- To investigate the interaction between UNC119A and KRAS.
- To elucidate the role of UNC119A in KRAS-mediated apoptosis and cancer cell behavior.
Main Methods:
- Quantitative RT-PCR
- RNAi-based gene silencing
- Immunoprecipitation and fluorescence assays
- Cell biology assays (soft-agar colony formation, migration, invasion)
Main Results:
- UNC119A interacts with the active, C-terminally modified form of KRAS, independent of UNC119A's myristoylated peptide-binding pocket.
- UNC119A enhances KRAS binding to RASSF6, promotes RASSF6-MDM2 interaction, and induces apoptosis.
- Silencing UNC119A in KRAS-mutated cancer cells increases colony formation, migration, and invasiveness.
Conclusions:
- UNC119A facilitates KRAS-mediated, p53-dependent apoptosis through RASSF6.
- UNC119A exhibits a tumor-suppressive function in KRAS-mutated cancers.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Abnormal Proliferation
MAPK Signaling Cascades
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

